TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Summit Therapeutics ( (SMMT) ) has issued an announcement.
On November 7, 2025, Summit Therapeutics announced that Akeso, its partner, published results from the Phase III HARMONi-A trial conducted in China. The trial demonstrated that ivonescimab combined with platinum-doublet chemotherapy significantly improved overall survival in patients with EGFR-mutated non-small cell lung cancer compared to chemotherapy alone. The study, which was the first Phase III trial for ivonescimab, showed a median overall survival of 16.8 months versus 14.1 months for chemotherapy alone, achieving a hazard ratio of 0.74. This result highlights ivonescimab’s potential to address high unmet medical needs in cancer treatment, offering a favorable risk-benefit profile and demonstrating efficacy where other PD-1 therapies have not succeeded.
The most recent analyst rating on (SMMT) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Summit Therapeutics stock, see the SMMT Stock Forecast page.
Spark’s Take on SMMT Stock
According to Spark, TipRanks’ AI Analyst, SMMT is a Neutral.
Summit Therapeutics’ stock score reflects significant financial challenges, including lack of revenue and ongoing losses, balanced by a strong equity position. Technical indicators show positive momentum, supporting short-term interest. Valuation remains weak due to negative earnings and no dividend. Positive clinical developments from the earnings call bolster the score, highlighting potential for future growth.
To see Spark’s full report on SMMT stock, click here.
More about Summit Therapeutics
Summit Therapeutics Inc. operates in the biopharmaceutical industry, focusing on developing novel therapies for unmet medical needs. The company collaborates with partners like Akeso, Inc. to advance its pipeline, particularly in oncology, with products such as ivonescimab, a bispecific antibody targeting cancer treatment.
Average Trading Volume: 4,136,743
Technical Sentiment Signal: Hold
Current Market Cap: $13.45B
For a thorough assessment of SMMT stock, go to TipRanks’ Stock Analysis page.